Patents by Inventor Jonathan Brazaitis
Jonathan Brazaitis has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10416172Abstract: The present invention relates to an isolated naturally-occurring soluble truncated IL-23R? protein, which is a translated protein resulting from a mRNA splice variant of IL-23R?. The soluble IL-23R? proteins (e.g., ?9 and ?8,9) represents a novel soluble IL-23R? protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that ?9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23R? protein. More importantly, the present invention provides an utility application of the ?9 and ?8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, ?9 and ?8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of ?9 and ?8,9 in treating a human patient inflicted with Crohn's disease.Type: GrantFiled: March 31, 2011Date of Patent: September 17, 2019Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Patent number: 9868776Abstract: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23R? gene. Exon 9 skipping of the IL23R? gene ultimately causes specific induction of a novel soluble truncated IL-23R? (?9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a ?9 protein which inhibits IL-23R-mediated cell signaling. More particularly, ?9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease.Type: GrantFiled: October 21, 2015Date of Patent: January 16, 2018Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Patent number: 9605027Abstract: The present invention relates to novel linear and cyclic polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides (linear or cyclic), and use of same in inhibiting cell functions including production of IL-22 and IL-17F from immune cells as well as in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease, ulcerative colitis and multiple sclerosis.Type: GrantFiled: October 26, 2015Date of Patent: March 28, 2017Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Publication number: 20170038396Abstract: A naturally-occurring soluble truncated IL-23R? protein (i.e., ?9 IL-23R?) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23R? protein. More particularly, antibody-sandwich ELISA method and kits for ?9 IL-23R? as an antigen were developed to detect ?9 IL-23R? levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma.Type: ApplicationFiled: October 20, 2016Publication date: February 9, 2017Applicant: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Joyce Eskdale, Jonathan Brazaitis
-
Patent number: 9523073Abstract: A naturally-occurring soluble truncated IL-23R? protein (i.e., ?9 IL-23R?) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23R? protein. More particularly, antibody-sandwich ELISA method and kits for ?9 IL-23R? as an antigen were developed to detect ?9 IL-23R? levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma.Type: GrantFiled: March 31, 2011Date of Patent: December 20, 2016Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Joyce Eskdale, Jonathan Brazaitis
-
Publication number: 20160115218Abstract: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23R? gene. Exon 9 skipping of the IL23R? gene ultimately causes specific induction of a novel soluble truncated IL-23R? (?9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a ?9 protein which inhibits IL-23R-mediated cell signaling. More particularly, ?9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease.Type: ApplicationFiled: October 21, 2015Publication date: April 28, 2016Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Publication number: 20160039878Abstract: The present invention relates to novel linear and cyclic polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides (linear or cyclic), and use of same in inhibiting cell functions including production of IL-22 and IL-17F from immune cells as well as in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease, ulcerative colitis and multiple sclerosis.Type: ApplicationFiled: October 26, 2015Publication date: February 11, 2016Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Patent number: 9187750Abstract: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23R? gene. Exon 9 skipping of the IL23R? gene ultimately causes specific induction of a novel soluble truncated IL-23R? (?9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a ?9 protein which inhibits IL-23R-mediated cell signaling. More particularly, ?9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease.Type: GrantFiled: November 25, 2013Date of Patent: November 17, 2015Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Patent number: 9169292Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.Type: GrantFiled: February 20, 2013Date of Patent: October 27, 2015Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Patent number: 8946150Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.Type: GrantFiled: June 14, 2012Date of Patent: February 3, 2015Assignee: Medical Diagnostic Laboratories, LLC.Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Publication number: 20140187602Abstract: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23R?gene. Exon 9 skipping of the IL23R? gene ultimately causes specific induction of a novel soluble truncated IL-23R? (?9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a ?9 protein which inhibits IL-23R-mediated cell signaling. More particularly, ?9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease.Type: ApplicationFiled: November 25, 2013Publication date: July 3, 2014Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Patent number: 8618070Abstract: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23R? gene. Exon 9 skipping of the IL23R? gene ultimately causes specific induction of a novel soluble truncated IL-23R? (?9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a ?9 protein which inhibits IL-23R-mediated cell signaling. More particularly, ?9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease.Type: GrantFiled: May 2, 2011Date of Patent: December 31, 2013Assignee: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Publication number: 20130183755Abstract: The present invention relates to an isolated naturally-occurring soluble truncated IL-23R? protein, which is a translated protein resulting from a mRNA splice variant of IL-23R?. The soluble IL-23R? proteins (e.g., ?9 and ?8,9) represents a novel soluble IL-23R? protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that ?9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23R? protein. More importantly, the present invention provides an utility application of the ?9 and ?8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, ?9 and ?8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of ?9 and ?8,9 in treating a human patient inflicted with Crohn's disease.Type: ApplicationFiled: January 23, 2013Publication date: July 18, 2013Inventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Publication number: 20130172272Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.Type: ApplicationFiled: February 20, 2013Publication date: July 4, 2013Applicant: Medical Diagnostic LaboratoriesInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Publication number: 20130035365Abstract: The present invention relates to anti-sense oligonucleotides (AONs) used to induce exon 9 skipping in IL-23R? gene. Exon 9 skipping of the IL23R? gene ultimately causes specific induction of a novel soluble truncated IL-23R? (?9) protein, characterized by a lack in a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end as a result of frame-shift. The present invention provides a utility application of the use of AONs to induce production of a ?9 protein which inhibits IL-23R-mediated cell signaling. More particularly, ?9 protein blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of AONs in treating a mammal such as a human patient inflicted with Crohn's disease.Type: ApplicationFiled: May 2, 2011Publication date: February 7, 2013Applicant: Medical Diagnostic Laboratories LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Publication number: 20130029907Abstract: The present invention relates to novel polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. The present invention relates a composition containing the novel polypeptides, and use of same in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease.Type: ApplicationFiled: June 14, 2012Publication date: January 31, 2013Applicant: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Publication number: 20120171704Abstract: A naturally-occurring soluble truncated IL-23R? protein (i.e., ?9 IL-23R?) is shown to be present in a biological sample and can serve as a diagnostic tool for autoimmune diseases. There is provided an enzyme-linked immunosorbent assay (ELISA) and test kit for the serological detection of the soluble truncated form of IL-23R? protein. More particularly, antibody-sandwich ELISA method and kits for ?9 IL-23R? as an antigen were developed to detect ?9 IL-23R? levels in biological samples from a mammal and a human patient and are used as a diagnostic index. The present disclosed ELISA has utility as a diagnostic tool to detect Crohn's disease in patients using EDTA-plasma.Type: ApplicationFiled: March 31, 2011Publication date: July 5, 2012Applicant: Medical Diagnostic Laboratories, LLCInventors: Grant Gallagher, Raymond Yu, Joyce Eskdale, Jonathan Brazaitis
-
Publication number: 20120071422Abstract: The present invention relates to an isolated naturally-occurring soluble truncated IL-23R? protein, which is a translated protein resulting from a mRNA splice variant of IL-23R?. The soluble IL-23R? proteins (e.g., ?9 and ?8,9) represents a novel soluble IL-23R? protein, which is lacking a transmembrane domain and has a unique eight (8) amino acids (GLKEGSYC) at its C-terminus end (due to frame-shift). ELISA reveals that ?9 is present in blood and can serve as a diagnostic tool for auto-immune diseases including Crohn's disease. There is also provided a method of recombinant production for this soluble truncated form of IL-23R? protein. More importantly, the present invention provides an utility application of the ?9 and ?8,9 protein in inhibit IL-23R-mediated cell signaling. More particularly, ?9 and ?8,9 blocks STAT3 formation as well as Th17 maturation. There is provided a therapeutic application of ?9 and ?8,9 in treating a human patient inflicted with Crohn's disease.Type: ApplicationFiled: March 31, 2011Publication date: March 22, 2012Applicant: Medical Diagnostic Laboratories LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis
-
Patent number: RE49026Abstract: The present invention relates to novel linear and cyclic polypeptides that bind to IL-23 receptor and inhibit the binding of IL-23 to its corresponding receptor and cell signaling thereof. The novel polypeptides of the present invention has a core structure of WX1X2X3W, where W is tryptophan, and X1, X2 and X3 are amino acids, with the proviso that when one of X1, X2 or X3 is W, the remaining two of X1, X2 or X3 cannot be W. Preferred core structures include WVDYW or WQDYW. The present invention relates a composition containing the novel polypeptides (linear or cyclic), and use of same in inhibiting cell functions including production of IL-22 and IL-17F from immune cells as well as in treating IL-23 associated human diseases including, for example, inflammatory bowel diseases, psoriasis and Crohn's disease, ulcerative colitis and multiple sclerosis.Type: GrantFiled: October 6, 2017Date of Patent: April 12, 2022Assignee: MEDICAL DIAGNOSTIC LABORATORIES, LLCInventors: Grant Gallagher, Raymond Yu, Jonathan Brazaitis